FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322773735> ?p ?o ?g. }

• W4322773735 endingPage "440" @default.
• W4322773735 startingPage "432" @default.
• W4322773735 abstract "The CheckMate 274 trial demonstrated improved disease-free survival (DFS) with adjuvant nivolumab versus placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after radical surgery in both the intent-to-treat population and the subset with tumor programmed death ligand 1 (PD-L1) expression ≥1%.To analyze DFS by combined positive score (CPS), which is based on PD-L1 expression in both tumor and immune cells.We randomized a total of 709 patients 1:1 to nivolumab 240 mg or placebo every 2 wk intravenously for ≤1 yr of adjuvant treatment.Nivolumab 240 mg.Primary endpoints were DFS in the intent-to-treat population and patients with tumor PD-L1 expression ≥1% using the tumor cell (TC) score. CPS was determined retrospectively from previously stained slides. Tumor samples with both quantifiable CPS and TC were analyzed.Of 629 patients evaluable for CPS and TC, 557 (89%) had CPS ≥1, 72 (11%) had CPS <1, 249 (40%) had TC ≥1%, and 380 (60%) had TC <1%. Among patients with TC <1%, 81% (n = 309) had CPS ≥1. DFS was improved with nivolumab versus placebo for patients with TC ≥1% (hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.35-0.71), those with CPS ≥1 (HR 0.62, 95% CI 0.49-0.78), and patients with both TC <1% and CPS ≥1 (HR 0.73, 95% CI 0.54-0.99).More patients had CPS ≥1 than TC ≥1%, and most patients who had TC <1% had CPS ≥1. In addition, patients with CPS ≥1 experienced improved DFS with nivolumab. These results may, in part, explain the mechanisms underlying a benefit with adjuvant nivolumab even in patients who had both TC <1% and CPS ≥1.We studied survival time without cancer recurrence (disease-free survival; DFS) for patients treated with nivolumab versus placebo after surgery to remove the bladder or components of the urinary tract for bladder cancer in the CheckMate 274 trial. We assessed the impact of levels of the protein PD-L1 expressed either on tumor cells (tumor cell score; TC) or on both tumor cells and immune cells surrounding the tumor (combined positive score; CPS). DFS was impoved with nivolumab versus placebo for patients with TC ≥1%, CPS ≥1, and for patients with both TC <1% and CPS ≥1. This analysis may help physicians understand which patients would benefit most from treatment with nivolumab." @default.
• W4322773735 created "2023-03-03" @default.
• W4322773735 creator A5006337629 @default.
• W4322773735 creator A5007456999 @default.
• W4322773735 creator A5007596741 @default.
• W4322773735 creator A5012316179 @default.
• W4322773735 creator A5018275141 @default.
• W4322773735 creator A5024007442 @default.
• W4322773735 creator A5027716206 @default.
• W4322773735 creator A5027835055 @default.
• W4322773735 creator A5030962499 @default.
• W4322773735 creator A5037805744 @default.
• W4322773735 creator A5048855238 @default.
• W4322773735 creator A5052290056 @default.
• W4322773735 creator A5053347862 @default.
• W4322773735 creator A5064884168 @default.
• W4322773735 creator A5067456208 @default.
• W4322773735 creator A5083331837 @default.
• W4322773735 creator A5090761384 @default.
• W4322773735 creator A5091176592 @default.
• W4322773735 date "2023-05-01" @default.
• W4322773735 modified "2023-10-03" @default.
• W4322773735 title "Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score" @default.
• W4322773735 cites W2136859769 @default.
• W4322773735 cites W2289712604 @default.
• W4322773735 cites W2557730509 @default.
• W4322773735 cites W2582671354 @default.
• W4322773735 cites W2588916311 @default.
• W4322773735 cites W2783970157 @default.
• W4322773735 cites W2884883038 @default.
• W4322773735 cites W2988644538 @default.
• W4322773735 cites W3128131226 @default.
• W4322773735 cites W3132958914 @default.
• W4322773735 cites W3138703636 @default.
• W4322773735 cites W3163995648 @default.
• W4322773735 doi "https://doi.org/10.1016/j.eururo.2023.01.016" @default.
• W4322773735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36868932" @default.
• W4322773735 hasPublicationYear "2023" @default.
• W4322773735 type Work @default.
• W4322773735 citedByCount "0" @default.
• W4322773735 crossrefType "journal-article" @default.
• W4322773735 hasAuthorship W4322773735A5006337629 @default.
• W4322773735 hasAuthorship W4322773735A5007456999 @default.
• W4322773735 hasAuthorship W4322773735A5007596741 @default.
• W4322773735 hasAuthorship W4322773735A5012316179 @default.
• W4322773735 hasAuthorship W4322773735A5018275141 @default.
• W4322773735 hasAuthorship W4322773735A5024007442 @default.
• W4322773735 hasAuthorship W4322773735A5027716206 @default.
• W4322773735 hasAuthorship W4322773735A5027835055 @default.
• W4322773735 hasAuthorship W4322773735A5030962499 @default.
• W4322773735 hasAuthorship W4322773735A5037805744 @default.
• W4322773735 hasAuthorship W4322773735A5048855238 @default.
• W4322773735 hasAuthorship W4322773735A5052290056 @default.
• W4322773735 hasAuthorship W4322773735A5053347862 @default.
• W4322773735 hasAuthorship W4322773735A5064884168 @default.
• W4322773735 hasAuthorship W4322773735A5067456208 @default.
• W4322773735 hasAuthorship W4322773735A5083331837 @default.
• W4322773735 hasAuthorship W4322773735A5090761384 @default.
• W4322773735 hasAuthorship W4322773735A5091176592 @default.
• W4322773735 hasBestOaLocation W43227737351 @default.
• W4322773735 hasConcept C121608353 @default.
• W4322773735 hasConcept C126322002 @default.
• W4322773735 hasConcept C126894567 @default.
• W4322773735 hasConcept C142724271 @default.
• W4322773735 hasConcept C143998085 @default.
• W4322773735 hasConcept C168563851 @default.
• W4322773735 hasConcept C204787440 @default.
• W4322773735 hasConcept C207103383 @default.
• W4322773735 hasConcept C27081682 @default.
• W4322773735 hasConcept C2777701055 @default.
• W4322773735 hasConcept C2780030458 @default.
• W4322773735 hasConcept C2908647359 @default.
• W4322773735 hasConcept C44249647 @default.
• W4322773735 hasConcept C71924100 @default.
• W4322773735 hasConcept C90924648 @default.
• W4322773735 hasConcept C99454951 @default.
• W4322773735 hasConceptScore W4322773735C121608353 @default.
• W4322773735 hasConceptScore W4322773735C126322002 @default.
• W4322773735 hasConceptScore W4322773735C126894567 @default.
• W4322773735 hasConceptScore W4322773735C142724271 @default.
• W4322773735 hasConceptScore W4322773735C143998085 @default.
• W4322773735 hasConceptScore W4322773735C168563851 @default.
• W4322773735 hasConceptScore W4322773735C204787440 @default.
• W4322773735 hasConceptScore W4322773735C207103383 @default.
• W4322773735 hasConceptScore W4322773735C27081682 @default.
• W4322773735 hasConceptScore W4322773735C2777701055 @default.
• W4322773735 hasConceptScore W4322773735C2780030458 @default.
• W4322773735 hasConceptScore W4322773735C2908647359 @default.
• W4322773735 hasConceptScore W4322773735C44249647 @default.
• W4322773735 hasConceptScore W4322773735C71924100 @default.
• W4322773735 hasConceptScore W4322773735C90924648 @default.
• W4322773735 hasConceptScore W4322773735C99454951 @default.
• W4322773735 hasFunder F4320307115 @default.
• W4322773735 hasIssue "5" @default.
• W4322773735 hasLocation W43227737351 @default.
• W4322773735 hasLocation W43227737352 @default.
• W4322773735 hasLocation W43227737353 @default.
• W4322773735 hasLocation W43227737354 @default.

• next